Mumbai, May 26, 2025 – Emcutix Biopharmaceuticals Limited – a subsidiary of Emcure Pharmaceuticals Ltd., introduces its latest sun care solutions: SOLGLO Hybrid Sunscreen SPF 70 PA++++ and SOLGLO Invisible Sunscreen Gel SPF 50+ PA++++. These broad-spectrum sunscreens are designed to offer high-efficacy protection while nourishing the skin.

With increasing awareness of the long-term effects of sun exposure—such as premature ageing, hyperpigmentation, and the impact of urban aggressors like pollution and blue light—SOLGLO emerges as a powerful ally to keep such skin concerns at bay. These sunscreens go beyond traditional protection by offering a lightweight, cosmetically elegant feel, defending against UVA, UVB, pollution, and even blue light emitted by electronic devices, while additionally forming a makeup base.

SOLGLO Hybrid Sunscreen combines the benefits of physical and chemical UV filters, delivering high-performance, broad-spectrum superior sun protection and an ultra-matte finish that suits all skin types, including sensitive and acne-prone skin. SOLGLO Invisible Sunscreen Gel, on the other hand, helps to reduce shine and controls oil production, making it ideal for daily wear under makeup or on bare skin. It moisturises and nourishes skin while protecting from UV rays. Both products also provide an exposomial protection against the urban stressors with the help of the renouvellance i.e. the red algae which acts as an anti-pollutant. The sunscreens are dermatologically tested on Indian skin types and can be used across climatic zones. 

“Conscious urban consumers with the knowledge of long-term sun damage and skin disorders are gravitating more towards pharma-grade, dermatologist-prescribed sunscreens”, avers Amal Kumar, Vice President, Marketing – Emcutix Biopharmaceuticals Ltd., “This trend reflects a maturing market where SPF is no longer seen as a cosmetic add-on but a core component of skin health. Each variant of SOLGLO is uniquely formulated to suit specific therapeutic needs of the skin — reinforcing our commitment to a prescription-based, skin-first product portfolio.” 

The Indian sunscreen category is witnessing unprecedented momentum, fuelled by rising awareness, social media influence, and expanding e-commerce accessibility. While beauty-led formulations dominate consumer platforms, a distinct shift is underway, where prescription-led sunscreen brands are emerging as the trusted gold standard, bridging the gap between therapeutic skin care and daily protection. 

About Emcutix Biopharmaceuticals Limited

Emcutix Biopharmaceuticals Ltd., backed by Emcure Pharmaceuticals Ltd., is a dermatology company committed to delivering innovative skincare and aesthetic solutions in India. Established in 2024, Emcutix aims to become a world-class leader by introducing groundbreaking treatments, globally recognized brands, and a differentiated product portfolio spanning therapeutic and aesthetic dermatology. The company is focused on introducing category-defining solutions that enhance patient outcomes and redefine care in Prescription, Consumer, and Aesthetic Dermatology. With a patient-centric approach, strong marketing expertise, and strategic partnerships with global leaders, Emcutix is set to redefine dermatological care and address unmet skincare needs across India.

Media Contact: